These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34769263)

  • 1. Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer.
    Minnelli C; Cianfruglia L; Laudadio E; Mobbili G; Galeazzi R; Armeni T
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
    Milligan SA; Burke P; Coleman DT; Bigelow RL; Steffan JJ; Carroll JL; Williams BJ; Cardelli JA
    Clin Cancer Res; 2009 Aug; 15(15):4885-94. PubMed ID: 19638461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
    Minnelli C; Laudadio E; Mobbili G; Galeazzi R
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
    Whitsett TG; Cheng E; Inge L; Asrani K; Jameson NM; Hostetter G; Weiss GJ; Kingsley CB; Loftus JC; Bremner R; Tran NL; Winkles JA
    Am J Pathol; 2012 Jul; 181(1):111-20. PubMed ID: 22634180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases.
    Sah JF; Balasubramanian S; Eckert RL; Rorke EA
    J Biol Chem; 2004 Mar; 279(13):12755-62. PubMed ID: 14701854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin Sensitizes Non-small Cell Lung Cancer Cells to an Epigallocatechin-3-Gallate (EGCG) Treatment by Suppressing the Nrf2/HO-1 Signaling Pathway.
    Yu C; Jiao Y; Xue J; Zhang Q; Yang H; Xing L; Chen G; Wu J; Zhang S; Zhu W; Cao J
    Int J Biol Sci; 2017; 13(12):1560-1569. PubMed ID: 29230104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
    J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 9. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.
    Shimizu M; Deguchi A; Lim JT; Moriwaki H; Kopelovich L; Weinstein IB
    Clin Cancer Res; 2005 Apr; 11(7):2735-46. PubMed ID: 15814656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
    Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
    Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dimeric-(-)-epigallocatechin-3-gallate inhibits the proliferation of lung cancer cells by inhibiting the EGFR signaling pathway.
    Sun XL; Xiang ZM; Xie YR; Zhang N; Wang LX; Wu YL; Zhang DY; Wang XJ; Sheng J; Zi CT
    Chem Biol Interact; 2022 Sep; 365():110084. PubMed ID: 35970427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.
    Chen C; Peng S; Li P; Ma L; Gan X
    Mol Cell Biochem; 2020 Dec; 475(1-2):15-25. PubMed ID: 32761510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigallocatechin-3-gallate (EGCG) downregulates EGF-induced MMP-9 in breast cancer cells: involvement of integrin receptor α5β1 in the process.
    Sen T; Chatterjee A
    Eur J Nutr; 2011 Sep; 50(6):465-78. PubMed ID: 21170718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
    Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.
    Mittal S; Kamath A; Joseph AM; Rajala MS
    Int J Oncol; 2020 Oct; 57(4):989-1000. PubMed ID: 32945365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.